Biotin-Linked Monoclonal Antibody to Tumor Necrosis Factor Ligand Superfamily, Member 14 (TNFSF14)
Code | Size | Price |
---|
LAA827Hu72-100ul | 100ul | £169.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Minimum order quantity: 2 |
Quantity:
LAA827Hu72-200ul | 200ul | £229.00 |
Quantity:
LAA827Hu72-1ml | 1ml | £526.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CD258; TR2; HVEML; LIGHT; LTg; Herpes virus entry mediator ligand; Herpesvirus entry mediator ligand
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Tumor Necrosis Factor Ligand Superfamily, Member 14
Source:
Antibody labeling
Usage:
Western blotting: 1:50-400 <br/>Immunocytochemistry in formalin fixed cells: 1:50-500 <br/>Immunohistochemistry in formalin fixed frozen section: 1:50-500 <br/>Immunohistochemistry in paraffin section: 1:10-100 <br/>Enzyme-linked Immunosorbent Assay: 1:100-1:5000 <br/>Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Monoclonal Antibody to Tumor Necrosis Factor Ligand Superfamily, Member 14 (TNFSF14) | MAA827Hu21 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||